Aug 14, 2025 • Motley Fool
SOMEWHAT-BULLISH
Daré Bioscience Posts Narrower Q2 Loss
Daré Bioscience ( NASDAQ:DARE ) , a women's health-focused biopharmaceutical company developing new therapies and devices, announced its second quarter 2025 results on August 14, 2025. The headline news was a negative GAAP revenue figure of $21,172, falling far short of the $280,000 consensus ...
Aug 12, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Investors Heavily Search Organon & Co. ( OGN ) : Here is What You Need to Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Aug 08, 2025 • Zacks Commentary
BULLISH
OGN vs. HQY: Which Stock Is the Better Value Option?
Investors interested in Medical Services stocks are likely familiar with Organon ( OGN Quick QuoteOGN - ) and HealthEquity ( HQY Quick QuoteHQY - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
Aug 06, 2025 • Motley Fool
NEUTRAL
Organon ( OGN ) Fiscal Q2 Revenue Beats 1%
Organon ( NYSE:OGN ) , a pharmaceutical company focused on women's health, biosimilars, and established brands, released its fiscal Q2 2025 ( ended June 30, 2025 ) results on August 5, 2025. The company reported GAAP revenue of $1.59 billion, above analyst expectations of $1.552 billion, and ...
Aug 05, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Organon ( OGN ) Beats Q2 Earnings and Revenue Estimates
Organon (OGN) delivered earnings and revenue surprises of +6.38% and +2.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 04, 2025 • Zacks Commentary
BULLISH
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.